Clinical Investigation| Volume 364, ISSUE 3, P316-326, September 2022

Correlation of serum amyloid A1 and interleukin-1beta in response to anti-tubercular therapy



      Host biomarkers are needed to monitor the response to anti-tubercular therapy (ATT) for ensuring effective therapy and preventing drug-resistant tuberculosis. We sought to find the correlation between the serum levels of SAA1 and IL-1beta in response to ATT in adult patients with pulmonary TB (PTB) or extra-pulmonary TB (EPTB).


      Blood samples of 32 patients with PTB and 28 patients with EPTB were analyzed. The blood samples were collected at baseline, two months and six months following treatment initiation. SAA1 and IL-1beta levels were measured by enzyme linked immunosorbent assay (ELISA).


      In the PTB group, the mean levels of SAA1 decreased significantly (p <0.001) after the intensive phase (two months) and continuous phase (six months) of ATT in comparison with the baseline value. IL-1beta values also decreased significantly (p = 0.005) after the intensive phase (two months) compared with the baseline values. In the EPTB group, there was a significant reduction in the mean serum level of SAA1 (p <0.001) and IL-1beta (p = 0.001) after the intensive phase (two months) in comparison with the baseline value, whereas the reduction at six months was not significant.


      SAA1 and IL-1beta may be useful potential treatment-monitoring biomarkers, especially in the intensive phase of therapy for both PTB and EPTB.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pai M.
        • Behr M.A.
        • Dowdy D.
        • et al.
        Mycobacterium Tuberculosis.
        Nat Rev Dis Prim. 2016; 2: 160-176
        • Wallis R.S.
        • Maeurer M.
        • Mwaba P.
        • et al.
        Tuberculosis - advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
        Lancet Infect Dis. 2016; 16: 34-46
        • Wallis R.S.
        • Kim P.
        • Cole S.
        • et al.
        Tuberculosis biomarkers discovery: developments, needs, and challenges.
        Lancet Infect Dis. 2013; 13: 362-372
        • Zumla A.
        • Nahid P.
        • Cole S.T.
        Advances in the development of new tuberculosis drugs and treatment regimens.
        Nat Rev Drug Discov. 2013; 12: 388-404
        • Walzl G.
        • Ronacher K.
        • Hanekom W.
        • Scriba T.J.
        • Zumla A.
        Immunological biomarkers of tuberculosis.
        Nat Rev Immunol. 2011; 11: 343-354
        • Yamada H.
        • Mizumo S.
        • Horai R.
        • Iwakura Y.
        • Sugawara I.
        Protective role of interleukin-1 in mycobacterial infection in IL-1 α/β double-knockout mice.
        Lab Invest. 2000; 80: 759-767
        • Liu P.T.
        • Schenk M.
        • Walker V.P.
        • et al.
        Convergence of IL-1β and VDR activation pathways in human TLR2/1-induced antimicrobial responses.
        PLoS One. 2009; 4: 5810-5817
        • Jayaraman P.
        • Sada-Ovalle I.
        • Nishimura T.
        • et al.
        IL-1β promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation.
        J Immunol. 2013; 190: 4196-4204
        • Juffermans N.P.
        • Florquin S.
        • Camoglio L.
        • et al.
        Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis.
        J Infect Dis. 2000; 182: 902-908
        • Mayer-Barber K.D.
        • Barber D.L.
        • Shenderov K.
        • et al.
        Caspase-1 independent IL-1β production is critical for host resistance to Mycobacterium tuberculosis and does not require TLR signaling in vivo.
        J Immunol. 2010; 184: 3326-3330
        • Ben-Sasson S.Z.
        • Hu-Li J.
        • Quiel J.
        • et al.
        IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.
        Proc Natl Acad Sci USA. 2009; 106: 7119-7124
        • Patel H.
        • Fellowes R.
        • Coade S.
        • Woo P.
        Human serum amyloid A has cytokine-like properties.
        Scand J ImmunoI. 1998; 48: 410-418
        • Furlaneto C.J.
        • Campa A.
        A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-α, interleukin-lβ, and interleukin-8 by human blood neutrophil.
        Biochem Biophys Res Commun. 2000; 268: 405-408
        • Sack G.H.
        Serum amyloid a-a review.
        Mol Med. 2018; 24: 46
        • Sigal G.B.
        Biomarkers of tuberculosis severity and treatment effect: a directed screen of 70 host markers in a randomized clinical trial.
        EBio Med. 2017; 25: 112-121
        • Glickman M.S.
        • Jacobs WR.
        Microbial pathogenesis of mycobacterium tuberculosis: dawn of a discipline.
        Cell. 2001; 104: 477-485
        • Sharma P.
        • Verma M.
        • Bhilwar M.
        • et al.
        Epidemiological profile of tuberculosis patients in Delhi, India: a retrospective data analysis from the directly observed treatment short-course (DOTS) center.
        J Family Med Prim Care. 2019; 8: 3388-3392
        • Yassin M.A.
        • Datiko D.G.
        • Shargie E.B.
        Ten- year experiences of the tuberculosis control program in the southern region of Ethiopia.
        Int J Lung Dis. 2006; 10: 1166-1171
        • Chan-Yeung M.
        • Noertjojo K.
        • Chan S.L.
        • Tam C.M.
        Sex differences in tuberculosis in Hong Kong.
        Int J Tuberc Lung Dis. 2002; 6: 11-18
        • Gaur P.S.
        • Suryakant B.R.
        • Singh S.
        • Saxena P.
        • Agnihotri S.
        Incidence and Clinical profiles of Pulmonary and ExtraPulmonary Tuberculosis patients in North Indian population: a hospital based Retrospective study.
        Int J Res Dev Pharm L Sci. 2017; 6: 2773-2778
        • Prasad A.
        • Ross A.
        • Rosenberg P.
        • Dye C.
        A world of cities and the end of TB.
        Trans R Soc Trop Med Hyg. 2016; 110: 151-152
        • Dye C.
        • Lönnroth K.
        • Jaramillo E.
        • Williams B.G.
        • Raviglione M.
        Trends in tuberculosis incidence and their determinants in 134 countries.
        Bull World Health Organ. 2009; 87: 683-691
        • Sunnetcioglu A.
        • Sunnetcioglu M.
        • Binici I.
        • Baran A.I.
        • Karahocagil M.K.
        Comparative analysis of pulmonary and extrapulmonary tuberculosis of 411 cases.
        Ann Clin Microbiol Antimicrob. 2015; 14: 34-40
        • World Health Organization in collaboration with Ministry of Health and Family Welfare
        INDEX-TB: Guidelines on Extra Pulmonary Tuberculosis for India.
        World Health Organization in collaboration with Ministry of Health and Family Welfare, India2016 (Available from:) (Accessed on 11 Aug 2019)
        • Rao V.G.
        • Bhat J.
        • Yadav R.
        • et al.
        Prevalence of pulmonary tuberculosis - a baseline survey in central India.
        PLoS ONE. 2012; 7: 43225
        • RNTCP Technical and Operational Guidelines for TB Control in India
        Central TB division. Director General of Health Services.
        Ministry of Health and Family Welfare, India2016 (Available from:) (Accessed on 26 Aug 2019)
        • Bhargava M.
        • Bhargava A.
        Pyridoxine for patients suffering from drug-susceptible tuberculosis in India.
        Public Health Action. 2018; 8: 97-100
        • Shears P.
        Epidemiology and infection in famine and disasters.
        Epidemiol Infect. 1991; 107: 241-251
        • Harries A.D.
        • Nkhoma W.A.
        • Thompson P.J.
        • Nyangulu D.S.
        • Wirima J.J.
        Nutritional status in Malawian patients with pulmonary tuberculosis and response to chemotherapy.
        Eur J Clin Nutr. 1988; 42: 445-450
        • Kennedy N.
        • Ramsay A.
        • Uiso L.
        • Gutmann J.
        • Ngowi F.I.
        • Gillespie S.H.
        Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania.
        Trans R Soc Trop Med Hyg. 1996; 90: 162-166
        • Kanungo S.
        • Abedi J.A.
        • Ansari M.A.
        • Khan Z.
        Percentage body weight gain during tuberculosis treatment: can it be a useful tool to predict the outcome?.
        Natl J Community Med. 2018; 9: 363-367
        • Jorstad M.D.
        • Dyrhol-Riise A.M.
        • Abmus J.
        • Marijani M.
        • Sviland L.
        • Mustafa T.
        Evaluation of treatment response in extrapulmonary tuberculosis in a low-resource setting.
        BMC Infectious Diseases. 2019; 19: 426-432
        • Khan A.
        • Sterling T.R.
        • Reves R.
        • Vernon A.
        • Horsburgh CR.
        Lack of weight gain and relapse risk in a large tuberculosis treatment trial.
        Am J Respir Crit Care Med. 2006; 174: 344-348
        • Wen C.P.
        • David Cheng T.Y.
        • Tsai S.P.
        • et al.
        Are Asians at greater mortality risks for being overweight than caucasians? Redefining obesity for Asians.
        Public Health Nutr. 2009; 12: 497-506
        • Schaberg T.
        • Rebham K.
        • Lode H.
        Risk factors for side-effects of isoniazid, rifampicin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
        Eur Respir J. 1996; 9: 2026-2030
        • Lienhardt C.
        • Azzurri A.
        • Amedei A.
        • et al.
        Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo.
        Eur J Immunol. 2002; 32: 1605-1613
        • Vinhaes C.L.
        • Oliveira-De-Souza D.
        • Mattos P.
        • Nogueira B.M.F.
        Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study.
        Cytokine. 2019; 123: 1547-1559
        • Moeintaghavi A.
        • Arab H.R.
        • Rezaee S.A.R.
        • et al.
        The effects of smoking on expression of IL-12 and IL-1β in gingival tissues of patients with chronic periodontitis.
        Open Dent J. 2017; 11: 595-602
      1. Kathamuthu GR, Moideen K, Kumar NP, et al. Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment. PLoS One. 2020;15(5):e0233426.

        • Vinhaes CL
        • Oliveira-De-Souza D
        • Mattos P
        • et al.
        Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study.
        Cytokine. 2019; 123: 1547-1559
        • Miranda P
        • Gil-Santana L
        • Oliveira MG
        • et al.
        Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation.
        PLoS One. 2017; 12e0175278
      2. Claudia Manca, Mi-Sun Koo, Blas Peixoto, et al. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PLoS One. 2013;8(8):e74082.